CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s share price was down 2% on Monday . The stock traded as low as $39.21 and last traded at $40.76. Approximately 986,062 shares changed hands during trading, a decline of 49% from the average daily volume of 1,921,468 shares. The stock had previously closed at $41.59.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on CRSP. StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a research report on Monday, December 30th. Needham & Company LLC reiterated a "buy" rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, January 14th. Bank of America dropped their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Barclays decreased their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Wednesday, November 6th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $77.59.
Get Our Latest Stock Report on CRSP
CRISPR Therapeutics Stock Down 2.2 %
The firm has a 50 day moving average price of $42.77 and a 200 day moving average price of $46.66. The stock has a market cap of $3.39 billion, a P/E ratio of -14.03 and a beta of 1.67.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the prior year, the firm posted ($1.41) EPS. Equities analysts predict that CRISPR Therapeutics AG will post -5.08 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CEO Samarth Kulkarni sold 15,000 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now directly owns 181,540 shares of the company's stock, valued at $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On CRISPR Therapeutics
Institutional investors have recently bought and sold shares of the business. ARK Investment Management LLC raised its position in shares of CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after buying an additional 1,474,439 shares in the last quarter. State Street Corp raised its position in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after purchasing an additional 599,304 shares during the period. FMR LLC lifted its stake in shares of CRISPR Therapeutics by 1.0% in the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company's stock valued at $111,632,000 after purchasing an additional 23,075 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock worth $47,383,000 after purchasing an additional 35,196 shares during the period. Finally, Baker BROS. Advisors LP increased its position in shares of CRISPR Therapeutics by 743.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock valued at $39,608,000 after purchasing an additional 743,075 shares during the last quarter. Institutional investors own 69.20% of the company's stock.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Further Reading
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
